124 completed, 30 recruiting, 22 terminated, 22 unknown. 77 Phase 2, 59 Phase 3, 32 Phase 1, 15 Not applicable, 14 Phase 4.
Follow Chronic Urticaria: new trials by email Literature Review of Chronic Urticaria trials Research Report on Chronic Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria AK139, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Akeso | 201 | 2026-10-21 | 2026-10-15 |
| A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria MG-K10 Injection, Matching Placebo - Chronic Urticaria, Idiopathic | Phase 2 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 60 | 2026-09-23 | 2026-09-24 |
| Apremilast Added to Antihistamines in Chronic Urticaria Apremilast, Second-generation H1 antihistamine - Chronic Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Enrolling by invitation | Rashid Latif Medical College | 86 | 2026-09-23 | 2026-09-30 |
| Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks Remibrutinib, Omalizumab - Chronic Spontaneous Urticaria | Phase 3 | Recruiting | Novartis Pharmaceuticals | 382 | 2026-09-21 | 2026-10-13 |
| A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU) THB335 Lower Dose, THB335 Higher Dose, Placebo - Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria | Phase 2 | Recruiting | Calixis Inc. | 81 | 2026-09-15 | 2026-11-02 |
| A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs TLL-018 tablets, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 140 | 2026-09-10 | 2026-08-24 |
| A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines TLL-018, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 1 / Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 36 | 2026-08-15 | 2026-08-24 |
| Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT) Chronic Spontaneous Urticaria | Recruiting | Novartis Pharmaceuticals | 470 | 2026-08-04 | 2026-08-07 | |
| A Trial of HRS-3095 in Healthy Volunteers HRS-3095 - Chronic Spontaneous Urticaria | Early Phase 1 | Active not recruiting | Atridia Pty Ltd. | 36 | 2026-07-27 | 2026-10-30 |
| A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria HRS-3095 Tablet, HRS-3095 Tablet Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 190 | 2026-07-01 | 2026-05-29 |
| Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2). Alpha-0261, Placebo - Chronic Spontaneous Urticaria (CSU), Healthy Volunteers | Phase 1 | Not yet recruiting | AlphaMol Science Ltd. (Shanghai) | 48 | 2026-07-01 | 2026-07-06 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) BBT001, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Recruiting | Bambusa Therapeutics | 48 | 2026-06-29 | 2026-07-22 |
| A Prospective, Single-centre, Observational Cohort Study on the Efficacy and Safety of Bacterial Lysate (OM-85) in Combination With Antihistamines for the Treatment of Chronic Spontaneous Urticaria (CSU) Chronic Spontaneous Urticaria (CSU) | Not yet recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 132 | 2026-05-01 | 2026-05-07 | |
| Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. Autologous whole blood therapy, Desloratadine - Chronic Idiopathic Urticaria | Phase 3 | Not yet recruiting | Cairo University | 40 | 2026-04-30 | 2026-03-20 |
| A Study of MG-K10 in Chronic Spontaneous Urticaria MG-K10 Humanized Monoclonal Antibody Injection, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 3 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 226 | 2026-04-14 | 2026-04-22 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults EDP-978, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 1 | Recruiting | Enanta Pharmaceuticals, Inc | 98 | 2026-04-01 | 2026-04-21 |
| Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines Lesigercept, Placebo - Allergic Diseases, Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Yuhan Corporation | 150 | 2026-03-26 | 2026-04-15 |
| A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria Dupilumab - Chronic Spontaneous Urticaria | Terminated | Sanofi | 1 | 2026-03-18 | 2026-07-31 | |
| A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China Chronic Urticaria | Completed | Novartis Pharmaceuticals | 3485 | 2026-03-10 | 2026-04-15 | |
| Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. JYB1904, Placebo+JYB1904 - Chronic Spontaneous Urticaria | Phase 3 | Recruiting | Jemincare | 240 | 2026-03-09 | 2026-08-03 |
Showing 20 of 237. Sign in to see all of them.
Urticaria (44) · Cryopyrin-Associated Periodic Syndromes (35) · Chronic Inducible Urticaria (17) · Pruritus (15) · Cold Urticaria (8) · Familial dermographism (8) · Skin Diseases (7) · Angioedema (6) · Hypersensitivity (6) · Rhinitis, Allergic (6) · Multiple Pterygium Syndrome, Autosomal Dominant (5) · Dermatitis, Atopic (4) · Urticaria, Solar (4) · Bronchiolitis Obliterans Syndrome (3)
Disease Attributes (237) · Pathological Conditions, Signs and Symptoms (237) · Skin and Connective Tissue Diseases (237) · Chronic Disease (236) · Hypersensitivity, Immediate (236) · Pathologic Processes (236) · Skin Diseases, Vascular (235) · Immune System Diseases (234) · Hypersensitivity (231) · Skin Diseases (230) · Urticaria (193) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (40) · Skin Diseases, Genetic (40) · Genetic Diseases, Inborn (39)
Omalizumab (35) · remibrutinib (13) · canakinumab (11) · levocetirizine (10) · ligelizumab (10) · desloratadine (7) · dupilumab (6) · Injections (4) · Interleukin 1 Receptor Antagonist Protein (4) · Blood Specimen Collection (3) · Histamine Antagonists (3) · bilastine (3) · rilonacept (3) · AK002 (2) · Diphenhydramine (2)
Novartis Pharmaceuticals (48) · Charite University, Berlin, Germany (8) · Celldex Therapeutics (7) · Genentech, Inc. (6) · Allakos Inc. (4) · Hangzhou Highlightll Pharmaceutical Co., Ltd (4) · Sanofi (4) · Centre Hospitalier Universitaire de Besancon (3) · Chulalongkorn University (3) · Jasper Therapeutics, Inc. (3) · Longbio Pharma (3) · Mahidol University (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3) · Novartis (3)
United States (85) · Germany (67) · Spain (40) · France (37) · China (35) · Canada (33) · Poland (31) · United Kingdom (25) · Japan (22) · Taiwan (21) · Turkey (Türkiye) (21) · South Korea (20) · Argentina (18) · Italy (18) · Bulgaria (16)
Marcus Maurer, MD (3) · Jettanong Klaewsongkram, MD (2) · Kanokwalai Kulthanan, MD (2) · Raphaela T Goldbach-Mansky, M.D. (2) · Ahuva Cices, MD (1)
PMID 26054553, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 29655772, PMID 20819318, PMID 31161734, PMID 34773261, PMID 36440464, PMID 38008109, PMID 39193419, PMID 40043237, PMID 42297099, PMID 16899778, PMID 17490952, PMID 18668535, PMID 18668591, PMID 19133920, PMID 19494217, PMID 21356079, PMID 21859692, PMID 22152723, PMID 22294344, PMID 22583335, PMID 23031624, PMID 23053062, PMID 23147964, PMID 23380020, PMID 23432142, PMID 24906637, PMID 25023899, PMID 25046337, PMID 25223501, PMID 26810441, PMID 27010957, PMID 27143789, PMID 28118536, PMID 29134648, PMID 29638206, PMID 29649002, PMID 29671921, PMID 29974963, PMID 30618764, PMID 31577874, PMID 31874111, PMID 32252809, PMID 32272284, PMID 32827729, PMID 33247014
2019 (7), 2018 (3), 2023 (3), 2009 (2), 2014 (2), 2015 (2), 2017 (2), 2025 (2), R01AI116658 (1), ZIAAR041138-08 (1)